Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 276

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 276
---
 these laws, regulations and permitting requirements also may result in substantial fines, penalties or other sanctions or business disruption, which could have a material adverse effect on Kineta’s business, financial condition, results of operations and prospects. Any third-party CMOs and suppliers Kineta engages will also be subject to these and other environmental, health and safety laws and regulations. Liabilities they incur pursuant to these laws and regulations could result in significant costs or an interruption in operations, which could have a material adverse effect on Kineta’s business, financial condition, results of operations and prospects. Risks Relating to Kineta’s Common Stock The price of Kineta Common Stock may be volatile or may decline regardless of its operating performance. The trading price of the common stock will be volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond Kineta’s control. These factors include:

| • |     | actual or anticipated fluctuations in operating results; |

| • |     | failure to meet or exceed financial estimates and projections of the investment community or that Kineta provides 
 to the public;                                                                                                    |

| • |     | issuance of new or updated research or reports by securities analysts or changed recommendations for the industry 
 in general;                                                                                                       |

169

| • |     | announcements of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital 
 commitments;                                                                                                 |

| • |     | operating and share price performance of other companies in the industry or related markets; |

| • |     | the timing and magnitude of investments in the growth of the business; |

| • |     | actual or anticipated changes in laws and regulations; |

| • |     | additions or departures of key management or other personnel; |

| • |     | increased labor costs; |

| • |     | disputes or other developments related to intellectual property or other proprietary rights, including 
 litigation;                                                                                            |

| • |     | the ability to market new and enhanced solutions on a timely basis; |

| • |     | sales of substantial amounts of common stock by Kineta’s directors, executive officers or significant 
 stockholders or the perception that such sales could occur;                                           |

| • |     | changes in capital structure, including future issuances of securities or the incurrence of debt; and |

| • |     | general economic, political and market conditions. |

In addition, the stock market in general, and the stock prices of bio-pharmaceuticaland biotechnology companies in particular, have experienced extreme price and